Mologic leverages Alamar’s ultra-high affinity antibodies for SARS-CoV-2 diagnostics

Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Mologic, Ltd. (Mologic), part of the recently formed social enterprise Global Access Health and a leading developer of lateral flow and rapid diagnostic tests (RDTs), has announced a collaboration to utilize Alamar’s novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.

Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (“COVIOS” and “COVIGO” for personal self-testing) based on its lateral flow assay technology, utilizing high affinity, paired antibodies specific for the SARS-CoV-2 nucleoprotein antigen. Second generation tests with even greater sensitivity are now in development leveraging the latest generation of engineered antibodies with ultra-high affinity, discovered through Alamar’s proprietary Attobody™ platform, together with Mologic’s novel electronic lateral flow immunoassay (eLFIA) technology.

Professor Paul Davis, Chief Scientific Officer & Co-Founder of Mologic, said: “We are very pleased with the increased sensitivity attainable with Alamar antibodies, especially in view of the speed with which they can be developed. We look forward to continuing our collaboration to create the road map for unprecedented speed of response to new pandemic threats of whatever origin. Fast-track discovery and deployment of antibodies with the highest possible affinity and specificity will be the central pillar of this new Pandemic Preparedness, very much aligning with Mologic’s mission to better enable humanity to cope with the long-term presence of COVID-19.”

Dr. Yuling Luo, Founder, Chairman & CEO of Alamar, commented: “Rapid and highly sensitive COVID-19 detection will remain an essential global health challenge in the coming years, and we must learn from the global COVID-19 experience to ensure a better, robust Pandemic Preparedness. We are excited to continue working with Mologic to meet these needs.”

Alamar’s proprietary Attobody™ platform produces a highly diverse pool of antibodies with single digit picomolar affinity and exquisite specificity. Compared to traditional antibody engineering, the Attobody platform deploys an accelerated antibody design and engineering process to generate novel antibodies without the need for affinity maturation. 

About Alamar Biosciences

Alamar Biosciences is a privately held life sciences company with a mission to transform the field of proteomics to enable the early detection of cancer and other diseases. The company’s two proprietary technology platforms, NULISA™ and Attobody™, work seamlessly with the latest advances in genomics to achieve single-digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. The Attobodies have picomolar affinity and built-in high specificity and have the potential to expand antibody therapeutics to many targets intractable with conventional antibodies.

About Mologic, Ltd.

Mologic is a leading developer of advanced lateral flow and rapid diagnostic technologies. Leveraging its core technology platforms, the Company is structured as a social enterprise, working with international organizations across many disease targets, to help deliver fast, reliable and affordable diagnostics globally, at the point-of-care. The creativity, insight and knowledge that led to the first ground-breaking testing inventions in pregnancy and women’s health have guided Mologic since its formation in 2003, underpinning many of the organization’s existing and future innovations.

Mologic and its fellow social enterprise group, Global Access Diagnostics (GAD) are subsidiary organizations of Global Access Health, which was formed in 2021 by a consortium of social impact investors.

In conjunction with GAD, a high-volume manufacturing platform for affordable LFDs, Mologic offers world-leading technology and scientific research expertise for contract research and development, and local manufacturing, alongside a portfolio of device and reagent products for clinical and commercial applications. Mologic’s science has broad application across markets and disease states where rapid, accurate point-of-care testing can help make a difference in patient care and patient outcomes.

The Company is actively seeking strategic partners for its internal pipeline of respiratory, infection, infectious disease and women’s health diagnostic prototypes.

Mologic is headquartered in Bedford in the United Kingdom and has a US subsidiary, Mologic Inc. situated in Maine, New Gloucester